VMP ± Dara versus Rd ± Dara in transplant-ineligible patients with myeloma: a Phase IV trial

Mattia D’Agostino, MD, University of Turin, Turin, Italy, discusses the results of the randomized Phase IV Real MM trial (NCT03829371), which compared bortezomib-melphalan-prednisone (VMP) +/- daratumumab (Dara) to lenalidomide-dexamethasone (Rd) +/- Dara in transplant-ineligible patients with multiple myeloma treated in the real-world setting. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.